A. Naqash

Douglas B. Johnson, J. Moslehi, Melissa Y. Y. Moey, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Characterization of Immune Checkpoint Inhibitor-Related Cardiotoxicity in Lung Cancer Patients From a Rural Setting

B. Carabello, Melissa Y. Y. Moey, Justin D. McCallen, 2020, JACC. CardioOncology.

Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study

M. Kudo, N. Nishida, Yi‐Hsiang Huang, 2022, Journal for ImmunoTherapy of Cancer.

Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.

D. Ettinger, G. Otterson, J. Feliciano, 2020, JAMA oncology.

Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis

Jianjun Gao, G. Otterson, R. Chiari, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma

M. Kudo, P. Galle, N. Nishida, 2022, Liver international : official journal of the International Association for the Study of the Liver.

Peripheral blood interleukin 6, interleukin 10, and T lymphocyte levels are associated with checkpoint inhibitor induced pneumonitis: a case report

Li V. Yang, N. Sharma, D. Liles, 2021, Acta oncologica.

Metastatic melanoma in a 95 years old patient responding to treatment with talimogene laherparepvec followed by nivolumab

F. Collichio, N. Sharma, A. Naqash, 2017, Acta oncologica.

Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study.

M. Kudo, P. Galle, N. Nishida, 2022, European journal of cancer.

Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort

G. Otterson, R. Chiari, J. Sugisaka, 2020, Cancer Immunology, Immunotherapy.

Biological Rationale for Peripheral Blood Cell–Derived Inflammatory Indices and Related Prognostic Scores in Patients with Advanced Non-Small-Cell Lung Cancer

A. Addeo, A. Cortellini, L. Mezquita, 2022, Current Oncology Reports.

Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC

D. Costa, N. Rizvi, K. Kehl, 2020, JTO clinical and research reports.

Localized ablative immunotherapy drives de novo CD8+ T-cell responses to poorly immunogenic tumors

W. Hildebrand, S. Kaabinejadian, A. Hoover, 2022, Journal for ImmunoTherapy of Cancer.

Real-world use of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis.

P. Galle, L. Rimassa, N. Personeni, 2022, Journal of Clinical Oncology.

Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab

Yuehua Wu, M. Kudo, P. Galle, 2022, Cancers.

Epigenetics: A primer for clinicians.

B. Paluch, E. Griffiths, M. Nemeth, 2016, Blood reviews.

Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade

N. Sharma, J. Hardin, A. Hegde, 2019, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Association between immune-related adverse event timing and treatment outcomes

Yang Xie, D. Gerber, A. Cortellini, 2022, Oncoimmunology.

Advances in the management of alveolar soft part sarcoma.

A. Chen, H. Sankaran, Geraldine O’Sullivan Coyne, 2021, Current problems in cancer.

Phase II study of atezolizumab in advanced alveolar soft part sarcoma (ASPS).

J. Foster, J. Doroshow, A. Chen, 2021 .

A Rare Case of Squamous Cell Carcinoma of the Esophagus in a Patient With Goltz Syndrome

A. Naqash, S. Sundaram, P. Walker, 2019, ACG case reports journal.

Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study

M. Kudo, P. Galle, N. Nishida, 2022, Liver international : official journal of the International Association for the Study of the Liver.

Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma

M. Kudo, N. Nishida, L. Rimassa, 2021, Liver Cancer.

K. Goldberg, R. Pazdur, L. Rimassa, 2021, European journal of cancer.

Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors

L. Rubinstein, J. Doroshow, A. Chen, 2021, Clinical Cancer Research.

Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer

E. Zervos, S. Laks, A. Naqash, 2018, International journal of molecular sciences.

Outcomes of pregnancy during immunotherapy treatment for cancer: Analysis of clinical trials sponsored by the National Cancer Institute.

A. Chen, S. Ivy, E. Sharon, 2021, The oncologist.

Cardiac toxicity in patients with lung cancer receiving thoracic radiotherapy and immunotherapy

M. Peach, Melissa Y. Y. Moey, A. Ju, 2023, Frontiers in Oncology.

The emerging landscape of immune checkpoint inhibitor based clinical trials in adults with advanced rare tumors

A. Chen, N. Takebe, A. Mittra, 2020, Human vaccines & immunotherapeutics.

Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy

L. Rimassa, N. Personeni, T. Pressiani, 2020, Journal for ImmunoTherapy of Cancer.

Characterization of KRAS Mutation Subtypes in Non–small Cell Lung Cancer

Edward S. Kim, M. Socinski, Chul Kim, 2021, Molecular Cancer Therapeutics.

Case Report: Peripheral blood T cells and inflammatory molecules in lung cancer patients with immune checkpoint inhibitor-induced thyroid dysfunction: Case studies and literature review

Justin D. McCallen, Alexander Hoffman, Z. Hamedi, 2022, Frontiers in Oncology.

The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma

M. Kudo, N. Nishida, L. Rimassa, 2021, Cancers.

Co-relation of overall survival with peripheral blood-based inflammatory biomarkers in advanced stage non-small cell lung cancer treated with anti-programmed cell death-1 therapy: results from a single institutional database

Li V. Yang, G. Dy, A. Hegde, 2017, Acta oncologica.

Interleukin-6 as one of the potential mediators of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint blockade: evidence from a case report

Li V. Yang, E. Sanderlin, A. Naqash, 2017, Acta oncologica.

Hemophagocytic lymphohistiocytosis (HLH) secondary to Ehrlichia chaffeensis with bone marrow involvement

D. Liles, Meera Yogarajah, Bethany D. Vallangeon, 2017, Annals of Hematology.

Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade

L. Rimassa, N. Personeni, T. Pressiani, 2020, Cancers.

Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors

M. Kudo, N. Nishida, L. Rimassa, 2023, Frontiers in Oncology.

Single-cell transcriptomics reveals that tumor-infiltrating natural killer cells are activated by localized ablative immunotherapy and share anti-tumor signatures induced by immune checkpoint inhibitors

Kaili Liu, A. Hoover, N. Sadeghipour, 2023, bioRxiv.

L. Rimassa, N. Personeni, T. Pressiani, 2020, Journal of Hepatology.

Title: Characterization of KRAS Mutation Subtypes in Non-Small Cell Lung Cancer

Edward S. Kim, M. Socinski, Chul Kim, 2021 .

Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma

M. Kudo, P. Galle, N. Nishida, 2022, Hepatology International.

The role of gut microbiome in modulating response to immune checkpoint inhibitor therapy in cancer

D. Pinato, C. Stavraka, Saman Maleki Vareki, 2021, Annals of translational medicine.

Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study.

M. Filetti, D. Mallardo, P. Ascierto, 2021, JAMA oncology.

Abstract 485: Early antibiotic exposure delays disease progression following immune checkpoint inhibitor therapy for hepatocellular carcinoma: Evidence from an observational study

M. Kudo, N. Nishida, L. Rimassa, 2021, Clinical Research (Excluding Clinical Trials).

Real-world multiomic characterization of small cell lung cancer subtypes to reveal differential expression of clinically relevant biomarkers.

B. Halmos, T. Owonikoko, H. Borghaei, 2021, Journal of Clinical Oncology.

Reply to J. Delyon et al.

Hamzah Abu-Sbeih, B. Ricciuti, Yinghong Wang, 2019, Journal of Clinical Oncology.

DNA damage response and repair (DDR) gene mutations and correlation with tumor mutation burden (TMB) in non-small cell lung cancer (NSCLC).

J. Nieva, H. Borghaei, Y. Boumber, 2019, Journal of Clinical Oncology.

Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden

E. Sokol, G. Frampton, J. Trent, 2023, Journal for immunotherapy of cancer.

Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium

T. Choueiri, G. Sonpavde, Douglas B. Johnson, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer.

E. Ruppin, A. Cortellini, D. Pinato, 2023, Journal for immunotherapy of cancer.

Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC

D. Costa, N. Rizvi, K. Kehl, 2020, JTO clinical and research reports.

EGFR tyrosine kinase inhibitors (TKIs) versus durvalumab (durva) following concurrent chemoradiation (CRT) in unresectable EGFR-mutant non-small-cell lung cancer (NSCLC).

J. Neal, H. Wakelee, R. Herbst, 2023, Journal of Clinical Oncology.

Atezolizumab for Advanced Alveolar Soft Part Sarcoma.

J. Doroshow, M. Burgess, B. V. Van Tine, 2023, The New England journal of medicine.

Association of Baseline Tumor-Specific Neoantigens and CD8+ T-Cell Infiltration With Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors.

A. Tőkés, C. Kerepesi, M. Awad, 2024, JCO precision oncology.